JENA, Germany, Aug. 20 /CNW/ - Occlutech GmbH, the leading European
manufacturer of cardiac occlusion devices such as ASD, PFO and LAA occluders
today announced that it has initiated invalidation proceedings against AGA's
European patent in the U.K. Most of the broader claims interpreted into this
patent by AGA Medical were not accepted by the examiners of the European
Patent Office in the original patent approval process due to the existence of
prior art. This creates a significant and justified basis for Occlutech to
file for invalidation.
In addition, Occlutech is asking the U.K. court to rule that their
devices are outside the claims of AGA's patent, on the grounds of substantial
differences between the patent and the configuration of the Occlutech devices.
No date has yet been fixed for the hearing, but Occlutech will be seeking an
early ruling on these issues.
Occlutech's CEO Robert Moszner says; "We see a substantial chance that
AGA's European patent will be invalidated by this and as a result of AGA's own
actions and argumentation with the European Patent Office."
He continues, "Occlutech's technology base is very different from AGA's
where we do an individual braiding of each device. Our unique technology and
methods are superior and very different from anything else on the market and
we are eager to have the non-infringement confirmed in court in the U.K. as
early as possible."
Occlusion devices are used to treat structural heart disease, including
structural heart defects and abnormalities, such as Atrial Septal Defects
(ASD), or Patent Foramen Ovale (PFO), in a minimally invasive, non-surgical
way. The market for these devices, and the PFO occluders in particular, are
expected to expand significantly over the next few years.
For further information:
For further information: Robert Moszner, E-mail:
firstname.lastname@example.org, Phone: +49-3641-67-51-20; Susanne Goransson,
E-mail: email@example.com, Phone: +46-7043-36-521